AQST Capital raise

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

Published August 14, 2025 at 10:28 AM

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten offering of 21,250,000 shares of its common stock at an offering price of $4.00 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be $85 million. The Company intends to use the net proceeds received from the offering, together with the Company’s existing cash and cash equivalents, primarily to advance the launch and commercialization of Anaphylm™ (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis, assuming United States Food and Drug Administration (FDA) approval, and fo

Related Questions

How will the $85 million capital raise affect AQST’s liquidity and runway for product development? What is the expected dilution impact on existing shareholders from the issuance of 21.25 million new shares? How does the $4.00 offering price compare to AQST’s recent trading range and the current market price? Will the proceeds be allocated solely to the Anaphylm™ launch, or are there other pipeline or R&D initiatives that could benefit? How does this underwritten offering size and pricing compare to recent capital raises by peer biotech companies? What is the anticipated timeline for commercializing Anaphylm™ after FDA approval, and what milestones could drive the stock price? Are there any covenants or restrictions attached to the offering that could limit the company’s operational flexibility? How might the increased cash balance affect AQST’s valuation multiples (e.g., EV/EBITDA, price‑to‑sales) relative to peers? What is the potential impact on short‑term trading volume and volatility around the pricing announcement and subsequent closing? What are the market’s expectations for FDA approval of Anaphylm™ Sublingual Film and its potential revenue contribution?